Coherus Oncology, Inc. CHRS

CHRS Company Overview

Coherus Oncology, Inc. is a U.S.-based biopharmaceutical company focused on oncology therapeutics and immuno-oncology. The company operates primarily in the biotechnology and specialty pharmaceuticals industries, with a strategic emphasis on developing and commercializing cancer treatments through internally developed assets, licensed technologies, and acquisitions. Historically, Coherus was known for its biosimilars business, particularly products referencing established biologic therapies, but the company has increasingly shifted its focus toward proprietary oncology assets and immunotherapy platforms.

The company’s primary revenue drivers have included sales of biosimilar products and, more recently, oncology therapeutics. Coherus commercialized products such as UDENYCA (pegfilgrastim-cbqv), a biosimilar to Neulasta, and has invested in expanding its oncology pipeline through immuno-oncology candidates and targeted therapies. Key customer segments include oncology clinics, hospitals, specialty distributors, and healthcare systems primarily in the United States. Coherus has positioned itself as a lower-cost biologics competitor while transitioning toward higher-margin proprietary oncology assets. The company was founded in 2010 and evolved from a biosimilars-focused enterprise into a broader oncology-focused biotechnology company through licensing agreements, acquisitions, and internal pipeline development.